Mesalamine for Ulcerative Colitis: Doses, Forms, Side Effects

Most pages about mesalamine for ulcerative colitis are a reworded package insert, which leaves the three questions patients actually ask unanswered. Many of us want to know why a suppository can outperform a tablet, whether once-daily dosing is real equivalence or just convenience, and why the same drug that works in ulcerative colitis kept failing its Crohn's trials. The evidence answers all three.

Key Takeaways

• Oral mesalamine for ulcerative colitis beats placebo for maintenance: 37 percent relapsed versus 55 percent on placebo, across 8 studies and 1,555 participants (1)
• Once-daily and split dosing performed identically: 37 versus 39 percent relapse over 12 months, high-certainty evidence from 3,910 participants (1)
• For mild to moderate proctitis, the AGA strongly recommends mesalamine suppositories for patients choosing rectal therapy, and suggests topical over oral in distal disease (5)
• Mesalamine is not FDA approved for Crohn's disease, where 4 g/day gave a non-significant CDAI reduction of 19.8 points versus placebo (3)(4)
• Side effects tracked placebo closely (RR 0.93, 95% CI 0.73 to 1.18), with serious adverse events in 1 percent on 5-ASA versus 2 percent on placebo (1)
• Labels direct prescribers to check kidney function before starting and periodically after, which is routine blood work rather than cause for alarm (4)(6)

What Mesalamine Is and How It Works in the Colon

Mesalamine is 5-aminosalicylic acid, usually shortened to 5-ASA and spelled mesalazine outside the United States. Unlike most inflammatory bowel disease drugs, it acts topically on the lining of the bowel rather than suppressing the immune system body-wide. That is why it sits at the bottom of the ladder in our guide to ulcerative colitis treatment, and why the delivery system matters more here than for most medications.

Why It Is Called 5-ASA

The molecule is the active fragment of sulfasalazine, an older drug that paired it with a sulfa carrier. Oral 5-ASA preparations kept the benefit while shedding the carrier's side effects (1), and research published in the Cochrane Database of Systematic Reviews shows that trade-off honestly.

Sulfasalazine is still slightly more effective for maintenance: 48 percent relapsed on sulfasalazine versus 43 percent on 5-ASA at six to 18 months (RR 1.14, 95% CI 1.03 to 1.27; 12 studies, 1,655 participants; high-certainty evidence) (1). But it is less well tolerated, with adverse events in 29 percent versus 15 percent on 5-ASA (1): a small efficacy edge bought with roughly double the side effect rate.

Delivery Systems and Why They Differ

Because the drug works where it lands, products are engineered to release it in different places. Delayed-release tablets (Lialda, 1.2 g), extended-release capsules (Apriso 375 mg, Pentasa 250 mg), suppositories (Canasa 1 g) and enemas (Rowasa 4 g per 60 mL) deliver the same molecule to different stretches of bowel (8).

Here is the part patients rarely hear: Cochrane found there may be little or no difference in efficacy between the various 5-ASA formulations, for both induction and maintenance (1)(2). A newer or costlier brand is not a stronger drug. What differs is where it releases.

Oral Forms, Rectal Forms, and Why Both Together Often Work Better

For mild to moderate ulcerative proctitis, the American Gastroenterological Association makes a strong recommendation for mesalamine suppositories in patients choosing rectal therapy, and conditionally suggests topical mesalamine over oral mesalamine for distal disease (5). That order surprises most people, because a tablet feels like the more serious treatment. When inflammation sits in the rectum, a suppository puts the drug where it is needed.

Proctitis and Left-Sided Disease

The Canasa label specifies 1,000 mg rectally once daily at bedtime for three to six weeks for mildly to moderately active ulcerative proctitis, and states that safety and effectiveness beyond six weeks have not been established (6). That is an induction course as written, so longer use is the prescriber's call rather than an assumption.

Rectal 5-ASA also holds remission rather than only inducing it. Over 12 months, 62 percent of patients on rectal 5-ASA maintained symptomatic remission versus 30 percent on placebo (4 studies, 301 patients; RR 2.22, 95% CI 1.26 to 3.90) (7). The Cochrane authors rated that low-certainty because the data were sparse and heterogeneous, so it is a promising signal rather than a settled number.

Combining Oral and Rectal Mesalamine

For extensive or left-sided disease, the AGA conditionally suggests adding rectal mesalamine to oral 5-ASA, and for a suboptimal response suggests high-dose oral mesalamine, more than 3 g per day, together with rectal mesalamine (5).

In our community we have seen where that plan breaks down, and it is not the evidence: enemas and suppositories ask for a nightly routine that many people quietly abandon. If a combined regimen is on the table, saying out loud what feels sustainable beats agreeing in clinic and stopping at home.

Once-Daily Mesalamine for Ulcerative Colitis: What the Evidence Actually Shows

Taking the whole dose once a day performs the same as splitting it. About 37 percent of once-daily participants relapsed over 12 months versus 39 percent on conventional dosing (RR 0.94, 95% CI 0.88 to 1.01; 10 studies, 3,910 participants), rated high-certainty for both induction and maintenance (1). The AGA conditionally suggests once-daily dosing (5), so guideline and trial data point the same way.

One widely repeated claim does not survive contact with the data. Patients are often told once-daily dosing improves adherence, but Cochrane found probably little or no difference: 10 percent non-adherence versus 8 percent (RR 1.18, 95% CI 0.72 to 1.93) (1). It is simpler and works as well, but the trials do not show it makes people better at taking their medication.

Mesalamine dosage on the Lialda label reflects this: 2.4 g to 4.8 g, meaning two to four 1.2 g tablets, once daily for induction, and 2.4 g once daily for maintenance (4).

Why Mesalamine Works in Ulcerative Colitis but Not Well in Crohn's

Mesalamine is not an FDA-approved treatment for Crohn's disease. The Lialda label lists only mildly to moderately active ulcerative colitis, in adults and children weighing at least 24 kg (4). The trial evidence behind that label is as clear as the label itself.

High-dose controlled-release mesalamine at 4 g per day was not superior to placebo in Crohn's, producing a clinically non-significant CDAI reduction of 19.8 points (95% CI -46.2 to 6.7; 3 studies, 615 patients), and it was inferior to budesonide (RR 0.56, 95% CI 0.40 to 0.78; 1 study, 182 patients) (3). Low-dose mesalamine at 1 to 2 g per day was also not superior to placebo (3).

The mechanism explains the gap. Ulcerative colitis inflammation is continuous and confined to the mucosa of the colon, exactly what a topically acting drug can coat. Crohn's inflammation is patchy, extends through the full thickness of the bowel wall and can involve the small bowel, so a drug that works on the colonic surface has far less to act on. Our comparison of Crohn's disease and ulcerative colitis covers those differences.

There is a fair nuance. Cochrane saw a trend favouring sulfasalazine over placebo for induction in Crohn's, concentrated in Crohn's colitis: 45 percent versus 29 percent remission (RR 1.38, 95% CI 1.00 to 1.89; 2 studies) (3). Many people with Crohn's colitis were historically prescribed 5-ASA on that basis, and some still take it today.

If that describes you, nobody should stop a prescribed medication because of an article, this one included. That conversation belongs with your gastroenterologist, and our IBD medications comparison guide sets out what is used instead.

Side Effects and Kidney Monitoring

Mesalamine is genuinely well tolerated, and the numbers say so rather than the marketing. In placebo-controlled trials, adverse events showed probably little or no difference from placebo (RR 0.93, 95% CI 0.73 to 1.18; 5 studies, 1,132 participants), and serious adverse events hit 1 percent on 5-ASA versus 2 percent on placebo (1).

Common Side Effects

The reported side effects were flatulence, abdominal pain, nausea, diarrhea, headache and dyspepsia (1). Several overlap with ulcerative colitis itself, which is why the placebo comparison matters more than the list. Rectal forms add local irritation (7).

Renal Monitoring

Both the Lialda and Canasa labels instruct prescribers to evaluate renal function before initiating therapy and periodically while on therapy, and to discontinue the drug if renal function deteriorates (4)(6).

In practice that means routine blood work, not a warning sign. Mesalamine-induced interstitial nephritis is a rare but recognised reaction, and monitoring exists to catch it early. We are deliberately not publishing an incidence rate, because published estimates differ by roughly an order of magnitude and no single authoritative figure held up when we checked.

Acute Intolerance Syndrome

Both labels warn about mesalamine-induced acute intolerance syndrome, which may be hard to distinguish from a flare of ulcerative colitis, and advise monitoring for worsening symptoms and stopping promptly if it is suspected (4)(6).

This one has a practical trap. If symptoms worsen after starting, the intuitive conclusion is that the dose is too low, when the drug itself can be the cause. Our guide to ulcerative colitis symptoms describes what a typical flare looks like, and a worsening that starts with a new mesalamine prescription is worth a phone call.

The Lialda label also warns about hepatic failure in patients with pre-existing liver disease, and notes that taking azathioprine or 6-mercaptopurine alongside it may raise the risk of blood disorders and bone marrow failure (4).

Cost, Generics, and When to Step Up to Something Stronger

Generics have changed the cost picture. FDA approval data list 28 generic (ANDA) approvals for mesalamine across delayed-release tablets, extended-release capsules, suppositories and enemas, alongside 5 brand applications: Lialda, Apriso, Pentasa, Canasa and Rowasa (8).

Generic Availability

Since Cochrane found little or no difference in efficacy between formulations (1)(2), a generic of the right delivery type is not a compromise. We are not naming prices here: a price we cannot verify on the day of writing is worse than useless, and pricing varies by country, insurer and pharmacy.

What travels across borders is the structure. Brand and generic are priced differently, insurance tiers and prior authorisation rules differ by plan and national system, manufacturer assistance programmes exist in some countries, and price-comparison tools can surface large gaps for the identical product. Suppositories and enemas are often billed differently from tablets, so the cheapest effective route is a question for prescriber and pharmacist together.

When Mesalamine Is Not Enough

The AGA ladder has escalation built into it: standard-dose oral mesalamine at 2 to 3 g per day, then high-dose oral plus rectal mesalamine for a suboptimal response, and onward for patients who remain symptomatic despite optimised oral and rectal 5-ASA (5).

Needing the next step is not a personal failure. It is a normal, expected part of ulcerative colitis care, and the existence of a defined next step is the good news in that sentence. What comes after 5-ASA, including steroids, thiopurines, biologics and small molecules, is covered in our ulcerative colitis treatment guide.

What This Means for Your Next Appointment

The summary fits in a few lines: mesalamine works in ulcerative colitis and not in Crohn's, where it releases matters more than the brand, once daily matches split dosing, and a suppository can beat a tablet when disease sits in the rectum. Questions worth bringing to your next appointment:

1. Which part of my colon is inflamed, and does my current formulation release there?
2. Would a rectal form, alone or added to my tablets, suit my disease pattern?
3. Can my dose be consolidated into once daily?
4. When was my kidney function last checked, and when is it due again?
5. If this was prescribed for Crohn's disease, what is the reasoning in my case?

None of this replaces the judgment of the team who knows your history.

Frequently Asked Questions

How long does mesalamine take to work for ulcerative colitis?

Mesalamine is an induction and maintenance drug rather than a fast-acting one. The Canasa label prescribes a three to six week course for active ulcerative proctitis (6), and the oral induction trials assessed remission at similar time points (2). Several weeks without improvement is information for your prescriber, not grounds to change the dose alone.

Is mesalamine better taken once daily or split through the day?

The evidence says they are equivalent: 37 percent of once-daily participants relapsed over 12 months versus 39 percent on split dosing (RR 0.94, 95% CI 0.88 to 1.01; 3,910 participants; high-certainty) (1), and the AGA conditionally suggests once-daily (5). One caveat: the trials did not show better adherence (1), so the schedule you will actually keep is the right one.

Does mesalamine work for Crohn's disease?

Not well, and it is not FDA approved for it (4). High-dose controlled-release mesalamine at 4 g per day was not superior to placebo, with a non-significant CDAI reduction of 19.8 points, and was inferior to budesonide (3). A non-significant trend favoured sulfasalazine in Crohn's colitis (3). If it was prescribed for your Crohn's, ask why rather than stopping on your own.

Are mesalamine suppositories better than tablets?

For disease confined to the rectum, often yes. The AGA strongly recommends suppositories for mild to moderate ulcerative proctitis in patients choosing rectal therapy, and conditionally suggests topical over oral mesalamine in distal disease (5). For extensive or left-sided disease, the suggestion is adding rectal to oral 5-ASA rather than choosing between them (5).

What are the most common mesalamine side effects?

Flatulence, abdominal pain, nausea, diarrhea, headache and dyspepsia, with probably little or no difference from placebo overall (RR 0.93, 95% CI 0.73 to 1.18; 5 studies, 1,132 participants) (1). Serious adverse events occurred in 1 percent on 5-ASA versus 2 percent on placebo (1). Rectal forms add anal irritation and local discomfort (7).

Why does mesalamine require kidney monitoring?

Both the Lialda and Canasa labels direct prescribers to evaluate renal function before starting and periodically during therapy, and to stop the drug if it deteriorates (4)(6). Interstitial nephritis is a rare but recognised reaction, and monitoring catches it early. It is standard blood work, and the question worth asking is when yours is next due.

References

1. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 2020; CD000544.pub5. Read study
2. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 2020; CD000543.pub5. Read study
3. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database of Systematic Reviews, 2016; CD008870.pub2. Read study
4. LIALDA (mesalamine) delayed-release tablets, US prescribing information. DailyMed. Read label
5. Ko CW, et al. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019;156:748-764. Read guideline
6. CANASA (mesalamine) rectal suppositories, US prescribing information. DailyMed. Read label
7. Marshall JK, Thabane M, Steinhart AH, Newman JR. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 2012;11:CD004118.pub2. View on PubMed
8. US Food and Drug Administration. Drugs@FDA approvals data for mesalamine. openFDA, checked 2026-10-12. View data